| Prev Close | 4.58 |
| Open | 4.52 |
| Day Low/High | 4.38 / 4.75 |
| 52 Wk Low/High | 1.12 / 6.47 |
| Volume | 5.02M |
OPKO Health, Inc. (OPK)
4.55
0.03
0.66
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 670.04B |
| Market Cap | 3.06B |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Navigating the Market Is More Challenging
I continue to be impressed by how this market refuses to embrace negative narratives but that can change fast.
Opko Health Successfully Tests a Bottom and Is Ready to Rise
A correction in the shares of the provider of Covid-19 tests appears to be over and a new uptrend is underway.
Shares of Opko Health Are Still 'Testing Negative'
Opko's BioReference Labs has performed over 4.3 million Covid-19 tests thus far.
The Charts of Opko Health Suggest it Can Correct Further to the Downside
Let's review the charts and indicators.
Opko Health Sees Health of Its Charts Improve
The parent of BioReference Labs is sending some bullish signals amid a nice recent run higher in its shares.
Opko Health's Charts Are Not Looking Healthy
Opko's BioReference Laboratories is on the cutting edge of Covid-19 testing.
A Bit of Rating Action
JPMorgan downgrades Opko Health to neutral and initiates Berkshire Hathaway with a buy.
Closing Bell: Stocks Fall for the Day, but Gain in 2016; Apple, Opko Health Shares Drop
Stocks close out the day slightly down, but post gains for 2016.
Opko Health Has 3 Very Attractive Charts
But it now or buy it when it's higher.
Where Is the Insider Buying?
The market is off its worst levels of the day. Big biotech and biopharma are providing strength today, with Biogen , Gilead Sciences and Mylan all sporting solid gains in a down market. Energy has made a bit of a comeback, but still is down nearly 2...
Morning Movers: BAC, MRO, NKE, OPK
Markets are projecting a positive open as Brexit-worries have abated.
Biotech Gets a Lifeline
Solid earnings and the start of some M&A activity may be just what this sector needs to rise.
Opko Health Plunges, but Still Optimistic After New Drug Fails to Get FDA OK
The FDA found no problems with the drug, but raised questions about its manufacturer.
Opko Health Rallies on Expected FDA Approval
After weathering a rocky year, the Miami-based pharmaceutical company is awaiting approval for a drug to treat kidney disease.
The Trader Daily: Let's Welcome Biotechs to the House of Pain
The bulls can show them around the place.
Cramer: Strong Dollar Means Own Stocks Like UnitedHealth, Humana
Jim Cramer answers viewers' Twitter (TWTR) questions from the floor of the New York Stock Exchange.
Change at the Top for 2 Banks; High Hopes for Cisco
Along with the networking company's results, we start to get retail earnings.
Market Wrap: Greece Weighs on Stocks
Payment to IMF deferred as major averages slide.
Dish Jumps on Deal Reports; Crude Sells Off Ahead of OPEC Meeting
Dish Network (DISH) spiked on reports the company is discussing a potential merger with T-Mobile (TMUS).
Cramer: Airlines Like Southwest in Purgatory Until Gas Comes Down
Jim Cramer answers viewers' stock questions sent in on Twitter (TWTR) from the floor of the New York Stock Exchange.
Why All the Selling?
Reeling off the positives, even though the averages are in the red.
The Machines Kick In
This jerky and chaotic market makes it difficult to focus on individual stock trades.
Keep Digging for Opportunities
The dip-buying is good but we need to see stronger momentum and better leadership.
Where's the Pullback?
Skepticism remains strong, and that's squeezing the market higher.
